Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Maimonides Medical Center
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05657860CT.gov Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Overnutrition
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Guanfacine (this asset) | Maimonides Medical Center | Approved | BB · 69 |
| pf-08653944 | Pfizer | P2 | CCC |
| pf-08653945 | Pfizer | P2 | CCC |
| Betahistine | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | P1 | CC |
| Gly-Low | Hoskinson Health and Wellness Clinic | Early P1 | CC |
| Metyrapone | Eleonora Seelig | N/A | D |
| Hydrocortisone | Eleonora Seelig | N/A | D |
Other indications for Guanfacine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Nervous System Disorder | — | P4 | BB · 69 |
| Disruptive Behavior Disorder | — | P4 | BB · 69 |
| Multiple Congenital Anomalies/Dysmorphic Syndrome | — | P4 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Guanfacine in Overnutrition. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/guanfacine-overnutrition
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →